CollPlant Biotechnologies’ (CLGN) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of CollPlant Biotechnologies (NASDAQ:CLGN) in a report issued on Friday morning,Benzinga reports. The brokerage currently has a $11.00 price objective on the stock.

CLGN has been the topic of a number of other reports. D. Boral Capital reissued a “buy” rating and issued a $14.00 price target on shares of CollPlant Biotechnologies in a research note on Wednesday. EF Hutton Acquisition Co. I raised CollPlant Biotechnologies to a “strong-buy” rating in a research report on Monday, August 5th.

CollPlant Biotechnologies Trading Up 5.4 %

Shares of NASDAQ:CLGN opened at $4.48 on Friday. The business has a 50-day moving average price of $4.29 and a 200 day moving average price of $4.84. CollPlant Biotechnologies has a 12-month low of $3.31 and a 12-month high of $6.99. The company has a market capitalization of $51.30 million, a price-to-earnings ratio of -2.76 and a beta of 0.44.

Institutional Trading of CollPlant Biotechnologies

Several hedge funds have recently made changes to their positions in the business. Pinnacle Associates Ltd. increased its stake in CollPlant Biotechnologies by 6.4% during the 2nd quarter. Pinnacle Associates Ltd. now owns 564,360 shares of the company’s stock worth $2,805,000 after buying an additional 33,905 shares during the period. Villere ST Denis J & Co. LLC increased its position in shares of CollPlant Biotechnologies by 24.4% during the third quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock worth $2,407,000 after acquiring an additional 95,000 shares during the period. Finally, Benjamin Edwards Inc. purchased a new stake in shares of CollPlant Biotechnologies during the third quarter worth $112,000. Institutional investors and hedge funds own 21.69% of the company’s stock.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.